CARDIoGRAMplusC4D Consortium

CARDIoGRAMplusC4D Consortium
Name	CARDIoGRAMplusC4D Consortium
Type	Research consortium
Founded	2013
Location	International
Focus	Genetics of coronary artery disease and cardiovascular disease

CARDIoGRAMplusC4D Consortium

The CARDIoGRAMplusC4D Consortium is an international research collaboration that pooled genome-wide association study data to map genetic determinants of coronary artery disease, myocardial infarction, and related cardiovascular traits. The consortium built on prior collaborations among academic centers, biobanks, and population cohorts to integrate large-scale genomic, phenotype, and biomarker datasets for translational cardiovascular genetics. It engaged researchers across multiple institutions to accelerate discovery, replication, and functional follow-up of loci implicated in atherosclerosis and ischemic heart disease.

Overview

The Consortium combined data from genome-wide association studies involving millions of genotypes and hundreds of thousands of participants drawn from cohorts such as the UK Biobank, Framingham Heart Study, Atherosclerosis Risk in Communities, Rotterdam Study, and Jackson Heart Study. It worked alongside initiatives including the Global Lipids Genetics Consortium, International HapMap Project, 1000 Genomes Project, Exome Aggregation Consortium, and ENCODE Project to refine association signals and prioritize candidate genes for coronary artery disease, myocardial infarction, peripheral artery disease, and stroke. Leadership and contributors included investigators affiliated with Harvard Medical School, Broad Institute, Wellcome Sanger Institute, Karolinska Institutet, University of Cambridge, and University of Oxford.

History and Formation

The formation was influenced by earlier consortia such as the Wellcome Trust Case Control Consortium and the International Stroke Genetics Consortium, as well as pivotal studies from researchers at Johns Hopkins University, Columbia University, Massachusetts General Hospital, and University of Michigan. Initial meta-analyses capitalized on genotyping platforms developed by Illumina and Affymetrix and leveraged imputation reference panels from the 1000 Genomes Project and Haplotype Reference Consortium. Major grants and institutional support came from organizations like the National Institutes of Health, Wellcome Trust, European Research Council, British Heart Foundation, and Canadian Institutes of Health Research.

Consortium Structure and Membership

The Consortium comprised academic investigators, clinical researchers, biobank managers, statistical geneticists, and computational biologists from institutions including Stanford University, University College London, Karolinska Institutet, Université de Montréal, University of Toronto, University of Edinburgh, and Imperial College London. Working groups organized efforts in statistical analysis, bioinformatics, functional genomics, and clinical translation, collaborating with core facilities at the Broad Institute, Sanger Institute, and European Molecular Biology Laboratory. Membership included principal investigators responsible for cohort contributions from the Million Veteran Program, China Kadoorie Biobank, BioBank Japan, and deCODE genetics, with liaison to consortia like GIANT, Psychiatric Genomics Consortium, and ENIGMA.

Major Studies and Findings

Key meta-analyses identified dozens of loci associated with coronary artery disease and myocardial infarction, implicating genes and pathways involving lipid metabolism, inflammation, vascular development, and thrombosis. High-profile findings implicated loci near PCSK9, LDLR, LPA, SORT1, NOS3, and ANRIL/CDKN2A-CDKN2B, providing links to therapeutic targets pursued by pharmaceutical companies and translational groups at institutions such as Pfizer, Regeneron, Amgen, and AstraZeneca. Results informed Mendelian randomization studies from groups at the University of Bristol and University of Copenhagen that clarified causal relationships for LDL cholesterol, triglycerides, and C-reactive protein with coronary disease. Follow-up functional work leveraged CRISPR screens at the Broad Institute, single-cell transcriptomics from the Human Cell Atlas, and epigenomic annotations from Roadmap Epigenomics to nominate effector genes and mechanisms.

Methods and Data Resources

Analytical methods included fixed-effect and random-effect meta-analysis, conditional and joint multiple-SNP analysis, fine-mapping using Bayesian approaches, polygenic risk scoring, and Mendelian randomization. Tools and resources employed comprised PLINK, METAL, GCTA, LD Score Regression, FINEMAP, and PrediXcan, integrated with reference datasets from 1000 Genomes, GTEx, ENCODE, and Roadmap Epigenomics. Data infrastructure utilized high-performance computing at centers such as the European Bioinformatics Institute, NIH’s Biowulf cluster, and cloud platforms supported by Amazon Web Services and Google Cloud, enabling secure handling of phenotype data from electronic health record systems like NHS Digital and Veterans Affairs databases.

Impact on Clinical Practice and Public Health

Findings from the Consortium influenced the development of genomic risk scores used in research settings and informed guideline discussions at professional bodies including the American College of Cardiology, European Society of Cardiology, and American Heart Association. Genetic evidence supported drug development efforts targeting PCSK9 inhibitors and informed biomarker prioritization for clinical trials coordinated by groups at the National Heart, Lung, and Blood Institute and pharmaceutical partners. Public health implications included refined risk stratification approaches in cohorts such as UK Biobank and All of Us Research Program and contributed to population-level studies in epidemiology centers at Johns Hopkins Bloomberg School of Public Health and the London School of Hygiene & Tropical Medicine.

Category:Genetics research consortia Category:Cardiovascular disease research